Trial Profile
The Use of Perfusion MRI Using Ferumoxytol and Small Molecular Weight Gadolinium (Gd) Agents to Assess Response to Pembrolizumab in Brain Metastases and Systemic Lesions in NSCLC: A Comparison of Imaging Modalities to Address Brain Metastases, Pseudoprogression, and Systemic Lesion Tumor Flare (Neuro-Check Pilot)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary) ; Pembrolizumab
- Indications Brain metastases; Non-small cell lung cancer
- Focus Diagnostic use
- Acronyms Neuro-Check Pilot
- 20 Jul 2021 Status changed from active, no longer recruiting to discontinued due to low accrual.
- 31 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2017 Status changed from not yet recruiting to recruiting.